GV:NASDAQVisionary Holdings Inc. Analysis
Data as of 2026-04-07 - not real-time
$0.34
Latest Price
8/10Risk
Risk Level: High
Executive Summary
Visionary Holdings (GV) is trading at $0.34, well below its 20‑day SMA of 0.37 and far under the 50‑day SMA of 0.79, indicating a short‑term bearish bias. The 30‑day volatility of 288% and a max drawdown of -92.9% underscore extreme price swings, while a beta of 0.56 suggests modest correlation to the broader market. Technical momentum is mixed: RSI sits at 40 (near‑neutral) and the MACD line sits above its signal, generating a bullish histogram signal, yet the overall trend remains bearish with price trapped between a support of 0.181 and resistance near 0.715. Fundamentals are weak – operating margin is deeply negative (-194%), debt‑to‑equity exceeds 900, and the company reports no earnings or cash flow positivity. The balance sheet is strained, with cash of only $0.33 M against debt of $48.6 M, and the price‑to‑book ratio of 0.38 reflects a market discount to net assets.
Recent news highlights a strategic pivot: GV announced a 2026‑2027 outlook targeting $30 million annual sales from its RAMU anti‑aging line and confirmed regained compliance with Nasdaq filing rules, removing an immediate regulatory threat. If the anti‑aging products achieve even a fraction of the forecast, revenue could improve, but the company must first reverse cash burn and resolve its capital structure before the upside can be realized.
Recent news highlights a strategic pivot: GV announced a 2026‑2027 outlook targeting $30 million annual sales from its RAMU anti‑aging line and confirmed regained compliance with Nasdaq filing rules, removing an immediate regulatory threat. If the anti‑aging products achieve even a fraction of the forecast, revenue could improve, but the company must first reverse cash burn and resolve its capital structure before the upside can be realized.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 7/10
Key Factors
- Price below short‑term moving averages
- Extreme short‑term volatility
- Negative earnings and cash flow
Medium Term
1–3 yearsNeutral
Model confidence: 6/10
Key Factors
- Nasdaq compliance restored
- Potential revenue from anti‑aging product line
- Continued cash‑burn and high leverage
Long Term
> 3 yearsPositive
Model confidence: 5/10
Key Factors
- Low price‑to‑book valuation
- Strategic expansion into health and AI education
- Long‑run upside if $30 M sales target is met
Key Metrics & Analysis
Financial Health
Revenue Growth-61.70%
ROE-137.27%
ROA-2.86%
Debt/Equity934.98
P/B Ratio0.4
Op. Cash Flow$-2968384
Free Cash Flow$-520235
Technical Analysis
TrendBearish
RSI40.3
Support$0.18
Resistance$0.71
MA 20$0.37
MA 50$0.79
MA 200$1.39
MACDBullish
VolumeIncreasing
Fear & Greed Index77.75
Valuation
GradeUndervalued
TypeBlend
Risk Assessment
Beta0.56
Volatility288.91%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.